RETRO-PROSPECTIVE OPEN STUDY TO ASSES GENETIC VARIABILITY AS A BASIS FOR PREDICTION OF THE RESPONSE TO GLP1 TREATMENT
The goal of this retrospective study is to assess whether a selection of genetic variants may allow us to identify individuals who will have a satisfactory response after GLP-1 treatment in terms of weight loss, sugar level reduction, and adverse events. Participants will The study consists of a single visit at the diabetes unit clinic at the involved study sites. The following will be performed for every subject at the study screening enrollment visit: * Informed consent * Study eligibility (Inclusion / Exclusion criteria) * Collection of demographic data (age (date of birth), gender, ethnic origin) * General and T2DM medical history review (per subject file) * Concomitant medication review (at enrollment) * Physical attributes (Body Weight, Height, BMI) * Allocation to study cohort and study subgroup * Saliva and blood collection for genetic tests * Self-reported questionnaire for Ozempic (Semaglutide) experience
• Diagnosed with type 2 diabetes (for participant in Cohort A) or Obese (for participant in Cohort B) and treated with Ozempic (Semaglutide) S.C. injection for at least 24 weeks.
• Subject is male/female between 18 to 80 years old (both inclusive) at the time of enrollment.
• Subject BMI above 30 kg/m2 at treatment initiation.
• Subject does not belong to any vulnerable population, is willing and able to provide written informed consent prior to any study procedure.
• Participant understands the nature of the procedure and is willing and able to comply with all requirement of the protocol.